Compare COCO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | BEAM |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2021 | 2019 |
| Metric | COCO | BEAM |
|---|---|---|
| Price | $76.29 | $29.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $57.75 | $50.75 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.60 | ★ 82.31 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | $33.77 |
| P/E Ratio | $151.99 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $31.82 | $15.60 |
| 52 Week High | $79.99 | $36.44 |
| Indicator | COCO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 67.16 | 51.34 |
| Support Level | $50.99 | $27.89 |
| Resistance Level | $79.99 | $32.01 |
| Average True Range (ATR) | 2.73 | 1.81 |
| MACD | -0.16 | -0.33 |
| Stochastic Oscillator | 68.57 | 40.92 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.